---
created: 2025-04-13
updated: 2025-04-13T10:51
id: lzp3*R~-m{
specialty: neuro
specialty_id: 218
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - source/ak-step1-v11::
  - theme/b&b::17-psych::04-pharm::03-antipsychotics
  - source/ak-step1-v11::
  - theme/firstaid::12-neuro-&-special-senses::06-pharm::17-spasmolytics-antispasmodics
  - source/ak-step1-v11::
  - theme/firstaid::12-neuro-&-special-senses::06-pharm::17-spasmolytics-antispasmodics::dantrolene
  - source/ak-step1-v11::
  - theme/firstaid::13-psychiatry::02-pathology::45-psychiatric-emergencies::neuroleptic-malignant-syndrome
  - source/ak-step1-v11::
  - theme/firstaid::13-psychiatry::02-pathology::45-psychiatric-emergencies::neuroleptic-malignant-syndrome::treatment
  - source/ak-step1-v11::
  - theme/firstaid::13-psychiatry::03-pharm::04-typical-antipsychotics
  - source/ak-step1-v11::
  - source/ome-banner::clinical::12-psychiatry
  - source/ak-step1-v11::
  - theme/physeo::09-pharm::13-psychiatric::02-neuroleptic-malignant-syndrome
  - source/ak-step1-v11::
  - theme/physeo::09-pharm::13-psychiatric::15-typical-antipsychotics
  - source/ak-step1-v11::
  - theme/physeo::09-pharm::14-neuro::10-dopamine-agonists
  - source/ak-step1-v11::
  - theme/pixorize::03-pharm::12-msk::dantrolene
  - source/ak-step1-v11::
  - theme/pixorize::03-pharm::15-other-neuro::amantadine
  - source/ak-step1-v11::
  - theme/pixorize::03-pharm::15-other-neuro::bromocriptine-(ergot-dopamine-agonists)
  - source/ak-step1-v11::
  - theme/pixorize::03-pharm::16-psych::typical-antipsychotics
  - source/ak-step1-v11::
  - theme/sketchypharm::06-neuro/psych::05-antipsychotics-&-parkinsons::01-first-generation-antipsychotics
  - source/ak-step1-v11::
  - theme/uworld::10000-99999::11000-11999::11676
  - source/ak-step1-v11::
  - theme/uworld::10000-99999::20000-20999::20474
  - source/ak-step1-v11::^other::^highyield::1-highyield
  - source/ak-step1-v11::^systems::neuro::pharmacology
  - source/ak-step2-v11::!shelf::fm::no-dupes
  - source/ak-step2-v11::!shelf::psych::no-dupes
  - source/ak-step2-v11::
  - theme/b&b::03-psych::04-psychopharmacology::02-antipsychotics::02-typical-antipsychotics
  - source/ak-step2-v11::
  - theme/resources-by-rotation::fm::ome::psych::pharm
  - source/ak-step2-v11::
  - theme/resources-by-rotation::psych::fapsych::pharm
  - source/ak-step2-v11::
  - theme/resources-by-rotation::psych::uworld::dorian
  - source/ak-step2-v11::
  - theme/resources-by-rotation::psych::uworld::zanki
  - source/ak-step2-v11::original-decks::dorian::fam::ome::psych::pharm
  - source/ak-step2-v11::original-decks::dorian::psych::fapsych::pharm
  - source/ak-step2-v11::original-decks::dorian::psych::uw
  - source/ak-step2-v11::original-decks::zanki-step-2::psych::uw-psych"
type: flashcard
---

# Question
Neuroleptic malignant syndrome may be treated with **dantrolene*** or a(n) **D2** agonist

---

# Answer
MOA: inhibition of Ca2+ release from sarcoplasmic reticulum of skeletal mm  e.g. bromocriptine    *However, discontinuation of the causative agent is the most critical intervention, as well as intensive supportive care. UpToDate says after that, start with benzodiazepines along with dantrolene in moderate/severe cases (then followed by addition of bromocriptine or amantadine)